If you are Texas Children’s Health Plan Member, we have tips that can help you deal with the severe weather. Learn more
Si eres miembro de Texas Children’s Health Plan, tenemos consejos que pueden ayudarte a lidiar con el clima severo. Aprende Más
Date: September 30, 2025
Attention: All Providers
Effective date: September 29, 2025
Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective September 29, 2025, the Texas Health and Human Services Commission (HHSC) removed non-preferred status from generic azelastine/fluticasone nasal products on the preferred drug list (PDL). This change is in response to a shortage brand Dymista products.
| Impacted Medication | Type of Change | Effective Date |
| AZELASTINE/FLUTICASONE 137-50MCG SPR | Generic now preferred | September 29, 2025 |
How this impacts providers: The change will allow providers to prescribe the generic without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Next step for providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.
For access to all provider alerts: www.texaschildrenshealthplan.org/provideralerts.